Latest on pharmacogenomic testing
A look at the current understanding of pharmacogenomic testing and how it can help with treating behavioral health issues.
Pharmacogenomics can have many applications and a presentation at the 2020 Virtual Conference on Pediatric Health Care by Kimberly Erlich, MSN, RN, MPH, CPNP, PMHS, offered a look at the current understanding of pharmcogenomic testing and how it can help with treating behavioral health issues.
She discussed how pharmacogenomics testing can help consider the most up-to-date treatments available because medications may have a different response because of genetic variations. Additionally, more than 40 neuropsychiatric medications currently list gene-drug interactions, which can be difficult to effectively use without the aid of something like pharmacogenic testing.
For clinicians who are considering pharmacogenic testing, Erlich said that there are 2 schools of thought. One considers testing to be appropriate before prescribing any medication in order to use it as a guide. The other school of thought considers testing appropriate to aid in monitoring patient response.
For more on the presentation, check out our sister publication Contemporary Clinic.
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Study finds reduced CIN3+ risk from early HPV vaccination
April 17th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
